Catheter Precision, Inc. Announces Two New Patents to be Issued by USPTO
Rhea-AI Summary
Catheter Precision (NYSE:VTAK), a medical device company specializing in cardiac electrophysiology, has received approval for two new patents from the United States Patent and Trademark Office (USPTO).
The first patent, "Methods of Ventricular Arrhythmia Localization Using a 3D Model," will be assigned to Kardionav, a joint venture between Catheter Precision and physicians. The second patent, "Neurostimulation Devices and Methods," focused on improving cardiac ventricular function in heart failure patients, will be assigned to Cardionomix, a majority-owned subsidiary of Catheter Precision.
Positive
- Strengthening of intellectual property portfolio with two new USPTO patents
- Strategic expansion in cardiac therapy through joint venture Kardionav
- Development of unique products for competitive medical device market through Cardionomix subsidiary
Negative
- None.
News Market Reaction – VTAK
On the day this news was published, VTAK declined 1.56%, reflecting a mild negative market reaction. Argus tracked a trough of -2.8% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $60K from the company's valuation, bringing the market cap to $4M at that time.
Data tracked by StockTitan Argus on the day of publication.
FORT MILL, S.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced that it has received notification from the United States Patent and Trademark Office of the allowance for issuance of two new patents.
One patent is entitled “Methods of Ventricular Arrhythmia Localization Using a 3D Model”. This patent is another milestone of adding to the VIVO technology intellectual property portfolio, and will be assigned to Kardionav, the joint venture between Catheter Precision and physicians to bring in new applications to cardiac ventricular therapies.
The second patent is entitled, “Neurostimulation Devices and Methods”, which is oriented toward improvement of cardiac ventricular function, especially in patients with heart failure. This patent will be assigned to Cardionomix, a majority owned subsidiary of Catheter Precision. Cardionomix holds a number of patents, with the intent to pursue heart failure therapy, primarily through stimulation of certain nerve endings found in the pulmonary arteries.
David Jenkins, CEO of Catheter Precision, commented, “We are pleased that additional intellectual property is being confirmed through the issuance of patents by the USPTO. This creates value for our different areas of technology and solidifies our beliefs that our products can be unique in a competitive medical device marketplace. We continue to have several applications on file and will continue to pursue new applications as a matter of our ongoing strategy.”
About VIVO™
Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
FAQ
What new patents did Catheter Precision (VTAK) receive from the USPTO?
How will the new VTAK patents impact their business?
Which subsidiaries will own Catheter Precision's new patents?
What is Catheter Precision's (VTAK) focus in medical technology?
